Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma

Chipps, Bradley E.; Israel, Elliot; Beasley, Richard; Panettieri, Reynold A.; Albers, Frank C.; Rees, Robert C.; Dunsire, Lynn; Danilewicz, Anna; Johnsson, Eva; Cappelletti, Christy; Papi, Alberto

doi:10.1016/j.chest.2023.03.035

Cited by 7 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to deliver sufficient doses of drugs to the lungs, liposomal nanomaterials, as the pulmonary drug delivery system, could increase the retention time of drugs in the lungs while reducing extrapulmonary side effects, resulting in improved therapeutic efficacy. 43 In conclusion, liposomal nanomaterials as the well-biocompatible, biodegradable, and nontoxic vesicles for encapsulating drugs, provided an attractive means for non-invasive drug delivery and sustained release in future asthma therapeutic drug development.…”

Section: In Vivo Safety Assessmentmentioning

confidence: 99%

Preparation of Budesonide-Loaded Liposomal Nanoparticles for Pulmonary Delivery and Their Therapeutic Effect in OVA-Induced Asthma in Mice

Zuo,

Gu,

Guo

et al. 2024

IJN

View full text Add to dashboard Cite

Inhaled corticosteroids, including budesonide (BUD), are widely employed for the treatment of asthma. However, the frequent use of corticosteroids is associated with numerous adverse effects and poses challenges to ongoing drug therapy and patient adherence. Budesonide liposomal nanoparticles (BUD-LNPs) were developed to improve the bioavailability of the drug and thereby improve the effectiveness of asthma treatment. Methods: BUD-LNPs were prepared via thin-film hydration, and the characterizations, stability, and in vitro release of BUD-LNPs were studied. In vitro cellular uptake was observed by laser-scanning confocal microscope (LSCM) and flow cytometry. And the in vitro anti-inflammatory activity of BUD-LNPs was evaluated by measuring the expression of pro-inflammatory cytokines in activated macrophages. Besides, the accumulation time in the lung of drugs delivered via liposomal carriers and free drugs was compared in vivo. And the in vivo therapeutic efficacy of BUD-LNPs was assessed in OVA-induced asthmatic mice. Finally, in vivo biosafety assessment was performed. Results: The particle size, PDI, and zeta potential of BUD-LNPs were 127.63±1.33 nm, 0.27±0.02, and 3.33±0.13 mV, respectively. BUD-LNPs exhibited excellent biosafety and anti-inflammatory activity in vitro. Furthermore, compared with the free drugs, the utilization of liposomal nano-vehicles for drugs delivery could effectively extend the duration of drugs accumulation in the pulmonary system. Additionally, treatment with BUD-LNPs alleviated airway hyperresponsiveness, reduced airway mucus secretion, and mitigated pulmonary inflammation in OVA-induced asthmatic mice. And the BUD-LNPs demonstrated superior therapeutic efficacy compared to free BUD. Conclusion: BUD-LNPs was successfully prepared with excellent stability and sustained release for 24 h in vitro. The data of antiinflammatory activity, asthma therapeutic effects and safety studies indicated that drug delivery mediated by liposomal nano-vehicles was a feasible and desirable strategy for medical strategy and showed great promise in the clinical therapy of asthma.

show abstract

Section: In Vivo Safety Assessmentmentioning

confidence: 99%